KR101429197B1 - Antibacterial Composition Containing Anthriscus sylvestris Extract - Google Patents

Abstract

The present invention relates to an antimicrobial composition comprising, as an active ingredient, an Anthriscus sylvestris extract and falcarindiol or deoxypodophyllotoxin isolated therefrom.
The prophylactic extract of the present invention and falcarindiol and deoxypodophyllotoxin isolated therefrom exhibit a strong antimicrobial activity against Helicobacter pylori, Staphylococcus aureus and Escherichia coli, Can be usefully used for preventing or treating diseases.

Description

Antibacterial Composition Containing Anthriscus sylvestris Extract "

The present invention relates to an antimicrobial composition comprising, as an active ingredient, an Anthriscus sylvestris extract and falcarindiol or deoxypodophyllotoxin isolated therefrom.

Direct or indirect damages caused by pathogenic microorganisms cause economic, environmental and medical problems. The loss of food in the food industry due to corruption, the harmfulness and environmental pollution of the human body due to the use of excessive chemical pesticides in the agricultural industry, and the emergence of antibiotic resistant strains due to abuse of antibiotics. .

Vancomycin-resistant staphylococcus aureus (VRSA), a highly resistant strain of vancomycin, is known to be the world's first treatment for Staphylococcus aureus, the most common cause of human infection. It was first reported by the Centers for Disease Control in 2002 The possibility of so-called super-bacteria spreading is becoming very high. This is the first time in Europe that vancomycin resistant enterococcus (VRE) resistant to vancomycin has been found in 1988 after methicillin-resistant aureus (MRSA), which is treated only by vancomycin, And vancomycin intermediate-resistants (aureus, VISA), which is resistant to vancomycin as reported in Japan, the United States, France and Korea in the latter half of 1990, is a new example of resistance to antibiotics, (Pfeltz, RF and Wilkinson, BJ 2004. The escalating challenge of vancomycin resistance in Staphylococcus aureus. Drug targets-infect. Disord. 4: 273-294 .; Levy , SB and Marshall, B. 2004. Antibacterial resistance worldwide: causes, challenges and responses. Nature Med. 10: 122-129.).

Most of the currently used antibiotics are manufactured through chemical synthesis, which is costly and has many limitations such as causing side effects. Therefore, in recent years, studies for separating new antimicrobial substances from natural products have been actively conducted. In order to isolate new antimicrobial substances from natural products, it should be considered that the antimicrobial spectrum is wide and safe even without long-term administration without adverse effects.

In 1982, Helicobacter pylori isolated from gastric mucosa of patients with type B gastritis by Marshall, Warren and Goodwin in Australia induced chronic gastritis type B, gastric ulcer and duodenal ulcer, It is known as a primary determinant of development. A major factor in the pathogenesis of stomach and duodenal diseases caused by Helicobacter pylori infection is urease, an urease, in the induction of gastric inflammation. Helicobacter pylori produces urea, which is equivalent to 6% of the total protein. The resulting urease breaks down the urea into ammonia and carbon dioxide to neutralize the environment surrounding the bacteria to prevent attack by hydrochloric acid in the gastric lumen, (Sidebotham RL, et al., J. Clin. Pathol., 44, pp. 52-57, 1991), which causes cytotoxicity directly to gastric epithelial cells. Due to the action of urease, stomach acid in the gastric lumen is regressed below the mucosal layer, and gastric acid causes gastric mucosal epithelial cells to be extensively damaged, resulting in gastritis and gastric ulcer. In addition, ammonia itself inhibits the oxygen consumption of the gastric mucosal layer and the ATP production of mitochondria (Tsujii M., et al., Gastroenterology, 102, pp 1881-1888, 1992) and ultimately forms monochloroamine (Hahm KB, et al., Am. J. Gastroenterol). In addition, it has been reported that ROS produce reactive oxygen species, which cause cellular damage and cause chronic inflammation, , 92, pp 1853-1857, 1997).

Helicobacter infections can be transmitted through animals or humans, through carelessness during medical care or through various routes of food (Dunn, BE, Cohen, H., and Blaser, MJ (1997). Clinical Microbiology Reviews, 10 ), 720-7, Kodaira, MS, Escobar, AMU, & Grisi, S. (2002) Revista de Sade Pade Pblica.36: 356-369).

Helicobacter pylori is specific to humans and is found mainly in certain places within the stomach, including diseases of the digestive tract such as peptic ulcers (e.g. gastric ulcer or duodenal ulcer), inflammation (e.g. gastritis) (Mucosa-associated lymphoid tissue) is a pathogenic factor in the pathogenesis of a lymphoma or chronic heart disease. Currently, studies on the treatment of Helicobacter pylori infection have been actively conducted, and many therapies for the purpose of elimination and prevention of recurrence have been reported.

As described above, although Helicobacter pylori is a very dangerous microorganism in gastrointestinal diseases, development of an appropriate antibacterial substance using natural materials is lacking. Currently, Helicobacter pylori therapies include bismuth, metronidazole, tetracycline or amoxicillin, bismuth, omeparazole, tetracycline or amoxicillin, And metronidazole have been reported. However, it has been pointed out that the appearance of resistant strains by the administration of antibiotics, the permeability of the drug in the stomach, and the reproductive growth of the bacteria whose growth has been suppressed after treatment are pointed out. For this reason, numerous efforts have been made to search for antibacterial substances specific to Helicobacter pylori. In recent years, there has been a growing interest in physiologically active ingredients in plants and their potential for regulating or preventing diseases Has come. Recently, antimicrobial activity against Helicobacter pylori of various natural products such as Thyme, Chinese tea, Cashew apple, Caboose and Chrysanthemum has been reported, but the research has not been done yet.

In order to solve the above-mentioned problems, the inventor of the present invention has conducted research to separate new antimicrobial substances from natural products, and found that the extracts of the present invention and falcarindiol or deoxypodophyllotoxin, Has an excellent antimicrobial effect on the pathogenic microorganism, thereby completing the present invention.

The object of the present invention is to provide an antimicrobial composition comprising an Anthriscus sylvestris extract and falcarindiol or deoxypodophyllotoxin isolated therefrom as an active ingredient.

In order to achieve the above object, the present invention provides a pharmaceutical composition for antimicrobial use comprising an extract of Anthriscus sylvestris as an active ingredient.

The present invention also provides a pharmaceutical composition for antimicrobial use comprising, as an active ingredient, falcarindiol or deoxypodophyllotoxin.

The present invention also provides a pharmaceutical composition for the prevention and treatment of stomach and duodenal diseases, which comprises a prodrug extract as an active ingredient.

The present invention also provides a pharmaceutical composition for the prevention and treatment of stomach and duodenal diseases comprising falcarindiol or deoxypodophyllotoxin as an active ingredient.

The present invention also provides a health functional food for prevention and improvement of stomach and duodenal diseases, which comprises as an active ingredient a prodrug extract.

The present invention also provides a health functional food for preventing and improving stomach and duodenal diseases comprising falcarindiol or deoxypodophyllotoxin as an active ingredient.

The present invention also provides an antimicrobial preparation comprising a prodrug extract as an active ingredient.

The present invention also provides an antibacterial agent comprising falcarindiol or deoxypodophyllotoxin as an active ingredient.

The prophylactic extract of the present invention and falcarindiol or deoxypodophyllotoxin isolated therefrom exhibit a strong antimicrobial activity against Helicobacter pylori, Staphylococcus aureus and Escherichia coli, Can be usefully used for preventing or treating diseases.

Fig. 1 is a fragmentary schematic view of the extract of T. hiraku.
Fig. 2 shows the results of antibacterial activity against Helicobacter pylori of the methanol extract of prokinase.
Fig. 3 shows the results of antibacterial activity against the Staphylococcus aureus and Escherichia coli of the former fraction.
FIG. 4 shows the results of antimicrobial activity of falcarindiol or deoxypodophyllotoxin, which was isolated from the extract of Tumor roe.

Hereinafter, the present invention will be described in more detail.

In one embodiment, the present invention provides a pharmaceutical composition for antimicrobial use comprising an extract of Anthriscus sylvestris as an active ingredient.

Anthriscus sylvestris is a common perennial plant distributed in Japan, Manchuria and China. It is 30-70cm high and has long brown hairs. Its rootstock is thick and short side-to-side. Flowers bloom in July-August, reddish purple, with many flowers on cones of stem at the end of stem, brown hairs on conchs, sepals are divided into 5 pieces, ovate fragments are 5 petals. It is called red horse hemp or red horse head horse which picks up the dried horse and makes dried, improves blood circulation, releases ebony blood, releases fever, releases poison, It is known that it has the effect of stopping and stopping the pain. It is also used to relieve sickness, muscular and bony symptoms, bruises, arthralgia, post-operative pain, and poisonous bites from poisoned snakes (Bae Ki-hwan, Korean Medicinal Plants, Kyongsoo, p204, 2000).

As used herein, the term "extract" means an active ingredient isolated from a natural product, i.e., a substance exhibiting the desired activity. The extract can be obtained by an extraction process using water, an organic solvent, or a mixed solvent thereof, and includes all the forms that are formulated with the dry powder of the extract. In addition, the above-mentioned extract also includes a fraction obtained by fractionating the extract obtained through the above extraction process.

The extract according to the present invention can be obtained through the following process.

The precursor is extracted with at least one solvent selected from the group consisting of alcohol, ethyl acetate, methylene chloride, methyl ethyl ketone, acetone and ether, and the mixture is concentrated under reduced pressure. The alcohol may be a lower or higher alcohol, preferably a lower alcohol selected from the group consisting of methanol, ethanol, isopropanol and butanol, and more preferably methanol. The alcohol may be a mixture with water. The concentrate may further be fractionated with hexane, methylene chloride, ethyl acetate, butanol or water, and then concentrated under reduced pressure. The fraction concentrate may be further purified by chromatography (paper, TLC, column, etc.) using silica or paper as a carrier and a mixed solution of chloroform: acetone: formic acid as a developing solvent have. Here, the distribution of the substances in the extract between the water contained in the carrier and the developing solvent takes place, and the substance is separated according to the difference in the distribution ratio. In the developing solvent, chloroform: acetone: formic acid may be mixed at a ratio of 50 to 100: 10 to 20: 5 to 10, and most preferably 75: 16.5: 8.5. The chromatography may be thin layer chromatography (TLC) or column chromatography using silica as a carrier. The TLC is a method in which a silica gel is thinly coated on a support such as a glass plate or a plastic, and the extract is dripped on the support, followed by development with a developing solvent. The column chromatography is a method in which silica is packed in a column, the extract is loaded on the column, and developed with a developing solvent. For mass production of the extract, column chromatography is preferably used.

The present invention also provides a pharmaceutical composition for antimicrobial use comprising, as an active ingredient, falcarindiol or deoxypodophyllotoxin. The above-mentioned falcarindiol or deoxypodophyllotoxin has the structure of formula (1) or (2). The above-mentioned falcarindiol or deoxypodophyllotoxin can be obtained from prodrug extract and can be synthesized or purchased from a manufacturer.

The extract according to the present invention and the falcarindiol or deoxypodophyllotoxin isolated therefrom exhibit a strong antimicrobial activity against Staphylococcus aureus and Escherichia coli. Accordingly, the extract according to the present invention and falcarindiol or deoxypodophyllotoxin isolated therefrom may be useful for the prevention or treatment of the bacterium.

In another aspect, the present invention provides a pharmaceutical composition for preventing and treating stomach and duodenal diseases, which comprises a prodrug extract as an active ingredient. The present invention also provides a pharmaceutical composition for the prevention and treatment of stomach and duodenal diseases comprising falcarindiol or deoxypodophyllotoxin as an active ingredient.

The extract according to the present invention and the falcarindiol or deoxypodophyllotoxin isolated therefrom exhibit antimicrobial activity against Helicobacter pylori. Therefore, prevention of gastric and duodenal diseases induced by Helicobacter pylori And may be useful for treatment. The gastric and duodenal diseases may include peptic ulcer and gastric cancer, and preferably one or more selected from the group consisting of gastritis, duodenal ulcer, gastric ulcer, duodenal ulcer, gastric cancer, gastric lymphoma and gastric cancer, May be preferably chronic atrophic gastritis. Since the discovery of Helicobacter pylori, it has been reported that Helicobacter pylori is the main cause of gastric and duodenal diseases, and Helicobacter pylori is known to live mainly in the gastric mucosa, specifically epithelial cells and mucosal layer. Accordingly, it is possible to prescribe an excellent substance having excellent antimicrobial activity against Helicobacter pylori which is a causative organism for treating gastric and duodenal diseases.

The pharmaceutical composition of the present invention may be formulated into oral dosage forms, sterile injectable solutions, suppositories, and transdermal dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols according to a conventional method have. Examples of carriers, excipients and diluents that can be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. If necessary, it is formulated using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient.

In one embodiment, the pharmaceutical composition of the present invention can be formulated into a solid preparation for oral administration. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules and the like. These solid preparations may contain at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin Are mixed and formulated. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used.

In another embodiment, the pharmaceutical composition of the present invention may be formulated into a liquid preparation for oral administration. Liquid preparations for oral administration include suspensions, solutions, emulsions and syrups. These liquid preparations may contain various excipients in addition to commonly used inert diluents (for example, purified water, ethanol, liquid paraffin) For example, wetting agents, sweeteners, fragrances, preservatives and the like may be included.

In another embodiment, the pharmaceutical composition of the present invention may be formulated into a preparation for parenteral, preferably intraperitoneal administration. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. As the sterilized aqueous solution, a suitable buffer solution such as Hank's solution, Ringer's solution or physically buffered saline can be used. As the non-aqueous solvent, propylene glycol, polyethylene glycol, olive oil, The same vegetable oil, an injectable ester such as ethyl oleate, or the like can be used. If desired, preservatives, stabilizers, wetting or emulsifying agents, salts for controlling osmotic pressure and / or buffers may be used. On the other hand, in the case of suppositories, witepsol, macrogol, tween 61, cacao paper, laurin, glyceroglatin and the like may be used.

The composition formulated in the above manner may be administered through various routes including parenteral or oral (transdermal, subcutaneous, intravenous, muscular, abdominal, etc.) in an effective amount. The "effective amount" as used herein refers to an amount that shows a preventive or therapeutic effect when administered to a patient. The dose of the composition according to the present invention can be appropriately selected depending on the route of administration, subject to be administered, age, sex, weight, individual difference, and disease state. Preferably, the composition of the present invention may contain the active ingredient in an amount of 0.1 to 10000 mg / kg body weight / day, more preferably 10 to 1000 mg / kg body weight / day RTI ID = 0.0 > of < / RTI >

In another aspect, the present invention provides a health functional food for prevention and improvement of stomach and duodenal diseases comprising an extract of Anthriscus sylvestris as an active ingredient. The present invention also provides a health functional food for preventing and improving stomach and duodenal diseases comprising falcarindiol or deoxypodophyllotoxin as an active ingredient.

When the composition of the present invention is used as a food or beverage additive, the above extract or the falcarindiol or deoxypodophyllotoxin may be directly added, used in combination with other food or food ingredients, Can be appropriately used. The amount of the prophylactic extract or the amount of falcarindiol or deoxypodophyllotoxin can be suitably determined according to its intended use (prevention, health or therapeutic treatment).

In the case of long-term intake for the purpose of health or for the purpose of controlling health, it is possible to take the prophylactic extract for a long period of time because there is no problem in terms of safety.

There is no particular limitation on the kind of the food. Examples of foods to which the above substances can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, , Alcoholic beverages and vitamin complexes.

In case of formulation with beverage, the liquid ingredient to be added in addition to the prophylactic extract is not limited to any one, but may include various flavors or natural carbohydrates such as ordinary beverages as an additional ingredient. Examples of such natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose and polysaccharides such as those commonly used in dextrin and cyclodextrins, , Sorbitol, and erythritol. The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention. Natural flavors (taumarin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.)) and synthetic flavors (e. G., Saccharin, aspartame, etc.) can be used as flavors other than those described above .

In another aspect, the food composition of the present invention may be formulated into various flavors such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate etc.), pectic acid and its salts, , Protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the food composition of the present invention may contain pulp for the production of fruit and vegetable drinks. These components may be used singly or in combination, and the proportion of such additives may be selected in the range of 10 to 20% by weight based on the total weight of the composition.

In another aspect, the present invention provides an antibacterial agent comprising an Anthriscus sylvestris extract as an active ingredient. The present invention also provides an antibacterial agent comprising falcarindiol or deoxypodophyllotoxin as an active ingredient.

Such preparations include, for example, but are not limited to, cosmetics, disinfectants, sterilizing detergents, and food preservatives. The cosmetic composition may comprise one or more excipients and additives commonly used in the field of cosmetic composition preparation together with the prophylactic extract of the present invention or falcarindiol or deoxypodophyllotoxin isolated therefrom, And can be easily manufactured according to a known method in the field. More specifically, the cosmetic may be at least one selected from the group consisting of basic cosmetics such as cleanser, pack, body oil and the like such as lotion, cream, essence, cleansing foam and cleansing water, color cosmetics such as foundation, lipstick, mascara and makeup base, shampoo, Hair products such as hair gel and soap, and the like. Preferably, cosmetic compositions comprising the prophylactic extract of the present invention or falcarindiol or deoxypodophyllotoxin isolated therefrom may be used to treat or prevent acne. Therefore, the cosmetic composition of the present invention may further comprise a plant-derived proteolytic enzyme such as Papain and Bromelain which can improve the therapeutic effect of acne, and a skin exfoliating agent such as a protease derived from a microorganism Can be added. In particular, substances such as salicylic acid and triclosan can be further added.

The disinfectant may be obtained by diluting the prophylactic extract of the present invention or falcarindiol or deoxypodophyllotoxin isolated therefrom as it is or diluting it with a dermatologically and pharmacologically acceptable diluent or solvent to a suitable concentration Can be manufactured. The disinfectant may be used on the surface of the organism, preferably on the skin of mammals, most preferably on human skin. In addition, the disinfectant may be used on surfaces of non-living organisms such as wood, metal, glass, ceramic, plastic, paper and cloth. The disinfecting agent may be applied to the surface of the organism or organism using methods including immersion, swab, spray and brushing. Preferably, the disinfectant may be used in hospitals and general households for use on wound surfaces, pre-operative skin disinfection, surgical instrument disinfection, and catheter disinfection.

In the case of the germicidal cleansing agent, in addition to the prophylactic extract according to the present invention or falcarindiol or deoxypodophyllotoxin isolated therefrom, one or more excipients and additives commonly used in the production of detergents And can be easily produced according to methods known in the art. The sterilizing detergent may be used for a kitchen or a food, and the sterilizing detergent for the kitchen may contain an anionic surfactant, a nonionic surfactant, an antioxidant, an antiseptic, an antiseptic, an antiseptic, , An amphoteric surfactant, and the like. Examples of anionic surfactants include alkylbenzenesulfonates, alpha olefin sulfates, sodium or ammonium lauryl ether sulfates, and examples of nonionic surfactants include fatty acid amides, alkylpolyglucosides, ethoxylated fatty alcohols, And the like. Examples of amphoteric surfactants include betaine surfactants, amine oxides, and the like. In addition to the surfactant, a diluent such as fragrance, pigment and water may be optionally added.

In the case of a food sterilizing detergent, a food-acceptable solvent or diluent is added to the extract of the present invention or falcarindiol or deoxypodophyllotoxin isolated therefrom at an appropriate concentration And then diluted. The food sterilizing detergent can be used for sterilizing and washing fruits, fish and meat, for example.

For the purpose of enhancing the preservability of foodstuffs, a food preservative may be added to a pharmacologically acceptable solvent or diluent to falcarindiol or deoxypodophyllotoxin isolated from the extract according to the present invention or a pharmacologically acceptable salt thereof And the like. The food preservative of the present invention may be formulated together with the raw material in the process of producing food or may be added as a separate aqueous suspension. In addition, the food preservative according to the present invention can be used to immerse the target food or spray the food preservative of the present invention to the target food.

Hereinafter, preferred embodiments and production examples are shown to facilitate understanding of the present invention. However, the following Examples and Preparation Examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the Examples and Production Examples.

Example  One. No.  Methanol and Fraction  purchase

The shrimp was shaken and then subjected to systematic extraction using methanol. The extract was extracted three times or more, and then concentrated under reduced pressure at 40 ° C with a vacuum concentrator (CCA-1100, EYELA) to obtain a methanol extract.

The above methanol extract was fractionated with hexane, methylene chloride, ethyl acetate, butanol or water, respectively, to obtain the former fraction. The fractionation scheme is shown in Fig.

Example  2. Helicobacter Pyory  Antibacterial effect on bacteria

100 μL of the fungus dispersion was dispensed on a Helicobacter pylori optimal plate, sterilized by a glass rod, and sterilized disc paper (diameter 8 mm) was raised. Each extract was sterilized with 0.45 μm membrane filter and concentrated with a vacuum evaporator. 30 μL of the extract was absorbed into disc paper. The control was absorbed in sterilized water and incubated at 37 ° C under aerobic condition for 24 hours.

As a result of examining the antimicrobial effect of the methanol extract of the present invention on Helicobacter pylori, as shown in Fig. 2, the clear zone was 8 mm in the sterilized water and showed no antibacterial effect of Helicobacter pylori. However, , The clear zone was 11 mm at 30 μL of 10 μg of total solution, indicating that the antibacterial effect against Helicobacter pylori was confirmed.

Example  3. Antibacterial effects on pathogenic bacteria

In the same manner as in Example 2, it was confirmed whether or not the prothyronectin extract had antimicrobial activity against representative pathogenic bacteria such as Staphylococcus aureus and Escherichia coli.

The fractions Hx, MC, EtOAc and BuOH fractions obtained in Example 1 were treated at a concentration of 10 μg / 30 μL for 24 hours, respectively. As shown in FIG. 3, the Hx, Mc, and EtOAc fractions of the present invention showed 10 mM growth inhibition for E. coli , respectively. In addition, the antimicrobial effect of S. aureus was confirmed by the inhibition of Hx and Mc fractions of 11 mM.

Example  4. Identification and Antibacterial Effect of Active Ingredients

In order to identify the active ingredient showing antimicrobial activity, falcarindiol or deoxypodophyllotoxin, which shows antimicrobial activity from the MC fraction as the active fraction, was identified by TLC and its structure was identified through NMR Respectively.

Falcarindiol; ^{1 H-NMR (500 MHz,} CDCl 3): δ 5.94 (H-2), 5.61 (H-10), 5.50 (H-9), 5.45 (H-1a), 5.27 (H-1b), 5.21 ( H-8), 4.94 (H -3), 0.87 (CH 3)

[Chemical Formula 1]

Deoxypodophyllotoxin; ^{1 H-NMR (400 MHz,} CDCl 3): δ 6.67 (1H, s, H-2), 6.52 (1H, s, H-5), 6.34 (2H, s, H-2 ', 6'), 5.95 (2H, d, J = 1.0 Hz, OCH 2 O), 5.93 (2H, d, J = 1.0 Hz, OCH 2 O), 4.60 (1H, d, J = 2.8 Hz, H-7 '), 4.45 (1H, td, H-9 ), 3.91 (1H, td, H-9), 3.80 (3H, s, 4'-OCH 3), 3.75 (6H, s, 3 '&4'-OCH 3), (1H, m, H-8, 8 '), 3.08 (1H, d, J = 11.2 Hz, H-

(2)

The antimicrobial activity of falcarindiol or deoxypodophyllotoxin, which is an active substance obtained through the above process, was confirmed, and as a result, inhibitory rings against Staphylococcus aureus, Escherichia coli and Helicobacter pylori were confirmed (Fig. 4) .

Therefore, it was confirmed through this experiment that the extracts and fractions of the wild plants of Korean native plants showed excellent antimicrobial activity against Helicobacter pylori, Staphylococcus aureus and E. coli, and falcarindiol or dioxy Deoxypodophyllotoxin also showed antimicrobial activity.

Hereinafter, examples of pharmaceutical composition, health functional food, and antimicrobial preparation containing the composition of the present invention will be described, but the present invention is not intended to be limited thereto but is specifically described.

Formulation example  One. Sanje  Produce

Or 2 g of pharmacological or pharmacokinetic

Lactose 100 mg

Talc 10 mg

The above components are mixed and filled in airtight bags to prepare powders.

Formulation example  2. Preparation of tablets

100 mg of ephedra extract or palmarindiol or deoxyglycolipotoxin

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.

Formulation example  3. Preparation of capsules

100 mg of ephedra extract or palmarindiol or deoxyglycolipotoxin

Crystalline cellulose 3 mg

Lactose 14.8 mg

Magnesium stearate 0.2 mg

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

Formulation example  4. Preparation of injections

100 mg of ephedra extract or palmarindiol or deoxyglycolipotoxin

180 mg mannitol

Sterile sterilized water for injection 2974 mg

Na ₂ HPO ₄ 2H ₂ O 26 mg

(2 ml) per 1 ampoule in accordance with the usual injection preparation method.

Formulation example  5. Liquid  Produce

100 mg of ephedra extract or palmarindiol or deoxyglycolipotoxin

10 g per isomer

5 g mannitol

Purified water quantity

Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was added with purified water to adjust the total volume to 100 ml, And sterilized to prepare a liquid preparation.

Formulation example  6. Manufacture of health food

Or 1 g of pharmacological or pharmacokinetic

Vitamin mixture quantity

Vitamin A acetate 70 μg

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

0.15 mg of vitamin B2

Vitamin B6 0.5 mg

Vitamin B12 0.2 μg

Vitamin C 10 mg

Biotin 10 μg

Nicotinic acid amide 1.7 mg

Folic acid 50 μg

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

Calcium carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

Formulation example  7. Health drink  Produce

Or 1 g of pharmacological or pharmacokinetic

Vitamin C 15 g

Vitamin E (powder) 100 g

19.75 g of ferrous lactate

3.5 g of zinc oxide

Nicotinic acid amide 3.5 g

Vitamin A 0.2 g

Vitamin B1 0.25 g

Vitamin B2 0.3g

Water quantification

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The solution thus prepared was filtered and sterilized in a sterilized 2 liter container, It is used in the production of the health beverage composition of the invention.

Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.

Formulation example  8. Manufacture of skin cleanser

0.5% < tb > < tb > < tb >

Glycerin 6 g

2.0 g of monoalkyl phosphate

Aqueous solution of sodium hydroxide 0.5 g

1.5 g of myristic acid, 12 g of a cleanser base containing a small amount of fragrance

The components were stirred in a homo mixer, heated at 60 ° C for 3 minutes, degassed, and cooled to 37 ° C to prepare a cleanser composition.

Formulation example  9. Manufacture of soap

0.5% < tb > < tb > < tb >

Soap base 99.5% by weight (including moisture)

The ingredients are mixed well in a mixer, extruded, cut and pressed in a soap maker to produce a solid soap composition.

Formulation example  10. Manufacture of kitchen cleaner

0.5% < tb > < tb > < tb >

20% by weight alkylethersulfonate (alkylethersulfonate)

4% by weight alkylpolyglucoside < RTI ID = 0.0 >

4% by weight of lauryldimethylamine oxide,

Cocamidopropyl betaine 7% by weight < RTI ID = 0.0 >

5% by weight of ethoxylated lauryl alcohol

EDTA 0.3 wt%

Small amount of pigment

Incense 0.5%

Purified water quantity

The above components are mixed to prepare a cleaning agent.

Claims (12)

An antimicrobial composition for Helicobacter pylori containing an extract of Anthriscus sylvestris as an active ingredient.
The composition according to claim 1, wherein the extract is extracted with an alcohol having 1 to 4 carbon atoms or a mixed solvent thereof.
delete delete delete delete delete delete delete delete Antibacterial agent for Helicobacter pylori containing an extract of Anthriscus sylvestris as an active ingredient.
delete

Images